Neonatal Jaundice

Overview & Definition

Neonatal jaundice (neonatal hyperbilirubinaemia) is the yellow discolouration of the skin, sclera and mucous membranes caused by an elevated serum bilirubin in the first 28 days of life. It is one of the most common conditions of the newborn — approximately 60% of term and 80% of preterm infants develop jaundice in the first week of age, and about two thirds of newborns appear clinically jaundiced during their first weeks of life. As postnatal hospital stays have shortened, readmission for neonatal jaundice has risen sharply.^[10][23]

The whole clinical problem turns on two distinctions that must be made on every jaundiced baby. First, when did it appear? Jaundice within the first 24 hours of life is always pathological — never physiological — and must be investigated as a matter of urgency, because early jaundice is almost always haemolytic and rises fast. Second, what type of bilirubin is it? Bilirubin circulates in two forms: unconjugated (indirect), which is fat-soluble, binds albumin loosely, and — when it accumulates — crosses the immature neonatal blood-brain barrier to stain and damage the basal ganglia and brainstem nuclei, causing kernicterus; and conjugated (direct), which is water-soluble, excreted in bile and urine, and never causes kernicterus but is always a marker of hepatobiliary disease. About 85% of neonatal jaundice is unconjugated and about 15% is conjugated.^[1]

The clinical task is therefore narrow and orderly: confirm jaundice with a serum bilirubin; decide whether it is physiological or pathological by timing, level, rate of rise and type; plot it on the Bhutani hour-specific nomogram; treat the dangerous unconjugated form with phototherapy or exchange transfusion to prevent kernicterus, which is permanent and entirely preventable; and exclude biliary atresia in every conjugated case because its surgical cure (the Kasai portoenterostomy) works only if performed early.^[1][6]

Classification

Enlarge

Neonatal jaundice is classified along two independent axes. The biochemical axis splits it into unconjugated and conjugated hyperbilirubinaemia, which tells you the mechanism and the danger. The behavioural axis splits it into physiological and pathological, which tells you whether to reassure the parents or to investigate urgently.^[1]

^{[25] [24] [19] [18] [11]}

The single rule that protects every jaundiced newborn is that physiological jaundice is a diagnosis of exclusion: it can be made only when the timing, level, rate of rise, duration and bilirubin fraction all fit, and the baby is clinically well. Anything else is pathological and must be investigated.^[1]

Epidemiology & Risk Factors

^{[10] [23] [24] [18] [11]}

Neonatal jaundice is near-universal. Approximately 60% of term and 80% of preterm infants develop jaundice in the first week of age, and about two thirds of newborns appear clinically jaundiced during their first weeks of life; as postnatal stays shortened, jaundice readmissions in the United States rose by 160% in a decade. Severe disease is uncommon: extreme hyperbilirubinaemia (TSB of 24.5 mg per dL or more) is an important risk factor for severe bilirubin encephalopathy, and in one large managed-care cohort TSB of 30 mg per dL or more occurred in only 11 of 111,009 newborns. Kernicterus is now rare in high-income countries — on the order of 1 in 100,000 infants — but newborns who are premature or have haemolytic disease remain at higher risk, and kernicterus remains a preventable cause of brain injury where screening and phototherapy are unavailable.^{[10][23][18][22][11]}

The risk factors for significant hyperbilirubinaemia cluster around four themes. Prematurity and low gestational age lower the threshold for both visible jaundice and treatment, because the preterm liver conjugates bilirubin even less efficiently and the preterm blood-brain barrier is more permeable. Haemolysis — ABO or Rh incompatibility, glucose-6-phosphate dehydrogenase (G6PD) deficiency, hereditary spherocytosis — multiplies the bilirubin load several-fold and is the dominant cause of dangerous early jaundice. Feeding and weight loss: exclusive breastfeeding, suboptimal intake, delayed meconium passage and excessive weight loss all increase enterohepatic reabsorption of bilirubin (the so-called breastfeeding jaundice of the first week). Clinical context adds instrumental or traumatic delivery, cephalohaematoma or extensive bruising (a large enclosed blood load resorbs into bilirubin), a sibling who needed phototherapy, East Asian ethnicity, and maternal diabetes. A haemolysing baby with a raised reticulocyte count, falling haemoglobin or a positive direct antiglobulin test (DAT) is on a different trajectory from a well, feeding, term infant, and the nomogram must be read with that risk in mind.^[1]

Pathophysiology

Enlarge

Enlarge

Understanding neonatal jaundice means tracing one molecule — bilirubin — from its origin to its danger. Bilirubin is the end-product of haem catabolism. When senescent red blood cells are broken down (chiefly in the spleen), their haemoglobin is split; the haem moiety is cleaved by haem oxygenase to biliverdin, which is in turn reduced by biliverdin reductase to unconjugated bilirubin. This unconjugated bilirubin is lipid-soluble, only sparingly soluble in water, and circulates in plasma tightly bound to albumin. It is taken up by the liver, where the microsomal enzyme uridine diphosphate glucuronyl transferase (UGT1A1) conjugates it with one or two molecules of glucuronic acid, producing conjugated (direct) bilirubin, which is water-soluble. Conjugated bilirubin is actively secreted across the canalicular membrane into bile, flows into the gut, and is converted by gut bacteria into urobilinogen and then stercobilin (the brown pigment of stool). A small fraction is reabsorbed and re-excreted by the liver — the enterohepatic circulation.^[1]

The neonatal liver-gut system is, by design, several steps behind an adult's, and this immaturity is the basis of physiological jaundice. Three mechanisms combine:^[1]

1. Increased bilirubin load. Neonates are born with a larger red-cell mass (haematocrit 50 to 60%) and a shorter red-cell lifespan — about 70 to 90 days versus 120 days in adults — so they generate roughly two to three times the bilirubin load per kilogram.
2. Immature hepatic conjugation. UGT1A1 activity at birth is only about 1% of adult activity and does not reach adult levels until roughly 6 to 12 weeks of age. The conjugating bottleneck is therefore most severe in the first days of life.
3. Increased enterohepatic circulation. The neonatal gut is sterile at birth and slow to transit; meconium holds bilirubin; and beta-glucuronidase present in breast milk and the immature gut deconjugates bilirubin in the intestinal lumen, regenerating lipid-soluble unconjugated bilirubin that is reabsorbed into the portal circulation and recycled to the liver. Delayed passage of meconium, suboptimal intake and dehydration all amplify this loop.^[1]

When production outstrips conjugation, unconjugated bilirubin accumulates. Most of it is bound to albumin and harmless; the danger is the small free (unbound) fraction, which is lipid-soluble and crosses cell membranes. Two further neonatal factors worsen the danger: low serum albumin (less binding capacity) and an immature blood-brain barrier with increased permeability. When free unconjugated bilirubin crosses the blood-brain barrier it is taken up by neurons and deposits preferentially in the basal ganglia (especially the globus pallidus and subthalamic nucleus), the brainstem auditory nuclei, the oculomotor nuclei, the hippocampus and the cerebellum. This deposition causes kernicterus — literally "yellow nuclei" — bilirubin-induced neuronal injury.^[1][7]

The clinical corollary is decisive: only unconjugated bilirubin causes kernicterus. Conjugated bilirubin is water-soluble, cannot cross the barrier, and is excreted harmlessly into bile and urine (which it turns dark). This is why a raised conjugated fraction, although always pathological, is dangerous for a different reason — it signals biliary obstruction that, if not relieved, leads to cirrhosis and liver failure, not to brain injury. Prematurity adds a special hazard: preterm infants develop kernicterus at lower TSB levels than term infants — the so-called low-bilirubin kernicterus — because their blood-brain barrier is more permeable and their albumin lower, so a "safe" level on a term nomogram may still injure a 30-week infant.^[7]

Clinical Presentation

The visible sign of neonatal jaundice is yellow discolouration of the skin and sclera that advances in a cephalocaudal (head-to-toe) direction — the Kramer principle of dermal advancement of icterus, on which clinical jaundice assessment (and even modern smartphone screening tools, which sample the forehead, sternum and abdomen in cephalocaudal order) is still based. Visual estimation is a screening tool only: treatment decisions must be based on a measured total serum bilirubin, the reference standard.^[21]

^[21]

A well baby with physiological jaundice looks otherwise normal — alert, feeding, afebrile, passing yellow stools and clear urine. The features that change the picture from "reassure" to "investigate urgently" are the tempo, the type of jaundice, and the general condition:^[1]

• Early onset (within 24 h): jaundice in the first day is pathological until proven otherwise; think ABO or Rh haemolysis, G6PD deficiency, or sepsis.^[1]
• A sick infant: lethargy, poor feeding, hypotonia, irritability, fever or hypothermia, grunting or apnoea — these suggest sepsis or acute bilirubin encephalopathy and are emergencies.^[1]
• Signs of acute kernicterus (bilirubin encephalopathy): in escalating order, lethargy, poor suck, hypotonia, a high-pitched cry, irritability, then hypertonia with back arching (opisthotonus), seizures, apnoea and ultimately coma. A baby showing these signs needs an immediate exchange transfusion, not further investigation.^[1][7]
• Conjugated jaundice clues: pale, clay-coloured (acholic) stools (no stercobilin reaches the gut — the single most important sign of biliary atresia), dark yellow-brown urine that stains the nappy (bilirubinuria), and hepatomegaly with a firm liver edge. A persistently jaundiced infant with pale stools must be referred urgently for surgical exclusion of biliary atresia.^[6]
• Haemolysis clues: pallor (anaemia), splenomegaly or hepatomegaly, tachypnoea or heart failure from severe anaemia, and a history of a previous affected sibling or maternal blood-group incompatibility.^[1]

Differential Diagnosis

The differential diagnosis follows the bilirubin type. Each cause has a distinguishing feature, and the bedside task is to match the clinical picture to one of them.^[1]

^[1]

A practical first split at the bedside: if the Coombs test is positive the cause is immune haemolysis (ABO or Rh); if Coombs negative but haemolysing think G6PD, hereditary spherocytosis or other non-immune haemolysis; if conjugated, refer for surgical exclusion of biliary atresia regardless of how well the baby looks.^[1][6]

Clinical & Bedside Assessment

The bedside assessment of a jaundiced newborn has one purpose: to decide whether this baby is safe or needs investigation and treatment now. Three questions frame the encounter.^[1]

1. How old is the baby in hours? Bilirubin risk is hour-specific: the Bhutani nomogram assigns each TSB to a risk zone only when plotted against age in hours, with significant hyperbilirubinaemia defined as TSB at or above the 95th percentile for age in hours. Always express age in hours, not days, when reading the nomogram.^[2]

2. How does the baby look? A full set of observations and a focused examination: temperature, activity, suck, tone, cry; weight and the percentage lost since birth; feeding pattern and stool/urine output; anterior fontanelle (dehydration); liver and spleen size; skin for bruising, cephalohaematoma or petechiae; any focus of infection. Lethargy, poor feeding, high-pitched cry or abnormal tone shifts the assessment immediately to "acute bilirubin encephalopathy until proven otherwise."^[1]

3. What are the risk factors? Gestational age; maternal and baby blood group; a previous sibling with jaundice, anaemia or hydrops; exclusive breastfeeding and intake; instrumental delivery, bruising or cephalohaematoma; ethnic ancestry (East Asian, Mediterranean, African — G6PD); maternal diabetes; a family history of haemolysis or inherited red-cell disorders.^[1]

^[2]

The Bhutani nomogram is the central interpretive tool: it plots TSB against age in hours for term and near-term infants and assigns a percentile risk — low (under 40th), intermediate (40th to 95th) or high (over 95th) — for developing significant hyperbilirubinaemia. A predischarge bilirubin in the high-risk zone predicts later treatment with high sensitivity, which is why universal predischarge bilirubin screening is now recommended.^[2]

Investigations

Investigation is targeted to the clinical picture. Every jaundiced newborn needs a total and fractionated serum bilirubin; the rest follows the timing, level and bilirubin type.^[1]

^[1]

A raised direct (conjugated) bilirubin is never physiological. The joint NASPGHAN/ESPGHAN guideline recommends that any infant still jaundiced after 2 weeks of age be evaluated with total and direct serum bilirubin, and that a direct bilirubin over 1.0 mg per dL (over 17 micromol per L) warrants timely evaluation and referral to paediatric gastroenterology or hepatology — cholestatic jaundice is always pathologic, biliary atresia accounts for 25 to 40% of it in early infancy, and its surgical treatment is time-sensitive.^[19]

Management — Resuscitation

Enlarge

Resuscitation in neonatal jaundice means one thing: recognising and treating the bilirubin level that is about to cause brain injury, before it does. The dangerous phenotype is the rapidly rising unconjugated bilirubin from haemolysis, and the single emergency is acute bilirubin encephalopathy, where every hour of delay in lowering the bilirubin adds permanent neurological damage.^[1]

The resuscitation sequence for a dangerously jaundiced infant is:^[1]

1. Assess airway, breathing, circulation — a baby with encephalopathy may have apnoea and need respiratory support.
2. Take blood for TSB with fractions, blood group, Coombs, FBC, reticulocytes, crossmatch, G6PD, sepsis screen, and venous blood gas and glucose.
3. Start intensive (double or triple) phototherapy immediately — every minute under blue light converts bilirubin to water-soluble photoisomers.^[3]
4. Correct dehydration and hypoglycaemia, support feeding; maintain temperature (phototherapy overheads warm, naked baby loses heat).
5. If the bilirubin is at or above the exchange transfusion threshold, or there are signs of encephalopathy — proceed to exchange transfusion without delay.^[1]
6. In immune haemolysis, give intravenous immunoglobulin (IVIG) to interrupt haemolysis while arranging exchange.^[5]

Management — Definitive & Stepwise

Definitive management is driven entirely by the bilirubin level read against the age-, gestation- and risk-specific threshold. Three interventions — phototherapy, intravenous immunoglobulin and exchange transfusion — form a ladder, with phenobarbital and feeding support as adjuncts and the underlying cause treated in parallel.^[1]

Phototherapy — first-line treatment

Phototherapy is the single most important treatment of unconjugated hyperbilirubinaemia. Light in the blue band converts unconjugated bilirubin in the skin into water-soluble photoisomers that are excreted without needing hepatic conjugation: fluorescent tubes emit across roughly 400 to 520 nm, fibre-optic pads across about 400 to 550 nm, and modern narrow-band blue LED light (450 to 470 nm) overlaps the peak absorption wavelength (458 nm) for bilirubin photoisomerization. The effect is photochemical, not thermal, and phototherapy is best prescribed like a drug — dosed cautiously and judiciously.^[9]

^{[11] [9]}

Contraindications and cautions: phototherapy treats unconjugated hyperbilirubinaemia, not liver disease. In infants with cholestasis or hepatic dysfunction, light exposure can produce the bronze baby syndrome — a grey-brown discolouration of skin, serum and urine. In the original series of affected infants, hepatic dysfunction was present in all of them; the infants were well despite the bronzing, and it disappeared within two months in all but one. Conjugated jaundice needs hepatobiliary investigation, not light. Watch for temperature instability and fluid loss.^[17]

Exchange transfusion — for severe or escalating disease

Exchange transfusion is the treatment of severe hyperbilirubinaemia, of bilirubin that rises despite intensive phototherapy, and of acute bilirubin encephalopathy. It removes bilirubin and circulating antibodies and corrects anaemia in one procedure. It has become a rare event in most developed countries but remains a frequent emergency rescue procedure for severe neonatal hyperbilirubinaemia in many under-resourced regions of the world.^[16]

^{[16] [4]}

Intravenous immunoglobulin (IVIG) — for immune haemolysis

^{[14] [5]}

Phenobarbital — enzyme induction

^[15]

Hydration, feeding and adjuncts

Adequate hydration and feeding are not optional. Dehydration and suboptimal intake increase enterohepatic circulation; correcting them lowers bilirubin. Continue breastfeeding throughout phototherapy; supplement with expressed breast milk or formula only when intake is inadequate. Routine IV fluids are not needed unless the baby is dehydrated or unable to feed. There is no role for albumin infusions, glycerine suppositories, or herbal remedies as routine treatment; aggressive feeding support is the evidence-based adjunct.^[1]

Treat the underlying cause

The definitive therapy is the one that stops bilirubin generation or obstruction: anti-D immunoprophylaxis for Rh-negative mothers prevents sensitisation and the next affected pregnancy; intrauterine transfusion rescues the severely hydropic fetus; antibiotics treat sepsis; thyroxine treats congenital hypothyroidism; eliminating galactose treats galactosaemia; and the Kasai portoenterostomy restores bile flow in biliary atresia. Without addressing the cause, phototherapy is only a holding measure.^[6]

Specific Subtypes & Scenarios

Biliary atresia — the conjugated jaundice not to miss

Biliary atresia is a progressive fibro-obliterative cholangiopathy of unknown cause in which the extrahepatic (and eventually intrahepatic) bile ducts are destroyed, producing complete obstruction. A term, previously well infant develops conjugated jaundice, pale (acholic) stools, dark urine and hepatomegaly between 2 and 6 weeks of age. The diagnosis rests on hepatobiliary ultrasound (abnormal or absent gallbladder, triangular cord sign), HIDA scan (no bowel excretion), and liver biopsy (bile duct proliferation, portal fibrosis), confirmed by intraoperative cholangiography. The definitive treatment is the Kasai portoenterostomy, in which the atretic ducts are excised and a Roux loop of jejunum is anastomosed to the porta hepatis to restore bile drainage. The single most important prognostic factor is age at surgery: success is highest when the Kasai is performed before 30 to 60 days of age, and falls steadily thereafter. Even with a successful Kasai, many children develop biliary cirrhosis and ultimately need liver transplantation; biliary atresia remains the commonest indication for paediatric liver transplant worldwide.^[6]

Haemolytic disease of the newborn — ABO and Rh

ABO incompatibility is the commonest immune haemolysis: a group O mother has naturally occurring anti-A and anti-B IgG that cross the placenta and haemolyse the red cells of a group A or B baby. It is usually mild to moderate, can affect the first pregnancy, and produces a positive DAT with spherocytes on the film. Rh (D) incompatibility requires prior sensitisation: a Rh-negative mother is exposed to Rh-positive red cells (at delivery, miscarriage, antepartum bleed or transfusion) and mounts anti-D IgG that, in a subsequent Rh-positive pregnancy, crosses the placenta and causes severe haemolysis ranging through anaemia, compensatory extramedullary haematopoiesis (hepatosplenomegaly), hydrops fetalis and stillbirth. The DAT is strongly positive. Anti-D immunoprophylaxis (anti-D immunoglobulin to the Rh-negative mother at 28 weeks and within 72 hours of delivery, and after any sensitising event) has reduced Rh disease dramatically where it is used. Intrauterine transfusion is reserved for severe mid-trimester anaemia detected by middle cerebral artery peak systolic velocity Doppler.^[1]

G6PD deficiency — a South Asian and Mediterranean hazard

Glucose-6-phosphate dehydrogenase deficiency is the commonest enzymopathy of red cells, inherited as an X-linked recessive trait, so it most often affects males. The enzyme normally regenerates NADPH, which keeps glutathione reduced and protects red cells from oxidative damage. When it is deficient, an oxidative trigger — a drug (sulphonamides, primaquine, nitrofurantoin, nalidixic acid, methylene blue, aspirin in high dose), fava beans, henna, or an infection — causes haemoglobin to denature and precipitate as Heinz bodies, the cells are removed by the spleen, and acute haemolysis follows with a sudden spike in unconjugated bilirubin. The Coombs test is negative (this is non-immune haemolysis), the blood film shows bite cells and Heinz bodies, and the assay confirms low enzyme activity. Kernicterus from G6PD haemolysis remains a significant problem in South Asia and the Mediterranean, where routine G6PD screening of at-risk newborns is advocated to prevent it. Management is avoidance of triggers, phototherapy and exchange transfusion for dangerous levels.^[8]

Breast milk jaundice versus breastfeeding jaundice

These two common entities are easily confused but distinct. Breastfeeding jaundice (suboptimal intake jaundice) occurs in the first week, peaks with the weight loss, and is driven by inadequate intake, dehydration, delayed meconium passage and increased enterohepatic circulation; it is corrected by feeding support (more frequent feeds, lactation review, supplementation if needed), not by stopping breastfeeding. Breast milk jaundice is a late, benign, prolonged unconjugated jaundice of the thriving breastfed infant, beginning after the first week and persisting for weeks to a couple of months; it is thought to relate to factors in breast milk that inhibit conjugation or increase enterohepatic reabsorption. It is a diagnosis of exclusion after haemolysis, hypothyroidism, infection and conjugated causes are ruled out; it needs no treatment, and breastfeeding should continue. A useful (but rarely needed) confirmatory test is a transient fall in bilirubin when breastfeeding is paused for 24 to 48 hours.^[1]

Prolonged jaundice — the framework

Jaundice persisting beyond 14 days in a term infant or 21 days in a preterm infant is prolonged jaundice and must be investigated rather than dismissed. The first split is unconjugated versus conjugated. Prolonged unconjugated causes include breast milk jaundice, hypothyroidism, G6PD deficiency, haemolysis, sepsis or UTI, and rare inherited disorders (Crigler-Najjar, Gilbert). Prolonged conjugated jaundice is always pathological and demands urgent hepatobiliary evaluation for biliary atresia (every day counts toward the Kasai deadline), neonatal hepatitis, TORCH infection, TPN cholestasis, alpha-1-antitrypsin deficiency, galactosaemia and metabolic disease. The most dangerous error in paediatrics is to reassure a parent about "breast milk jaundice" in a 4-week-old with pale stools who in fact has biliary atresia.^[6]

Complications & Pitfalls

The headline complication is kernicterus (bilirubin encephalopathy), and its staging is worth memorising because it dictates how hard to push treatment.^[1][7]

^[1]

Other complications and pitfalls deserve specific mention:^[1]

• Bronze baby syndrome: a grey-brown discolouration of skin, serum and urine that complicates phototherapy in infants with cholestasis or other hepatic dysfunction. In the original series it developed under phototherapy in infants who all had hepatic dysfunction, the infants were well despite the bronzing, and it disappeared within two months in all but one — so it should prompt review of the liver and conjugated fraction rather than panic.^[17]
• Apnoea of acute bilirubin encephalopathy: apnoea is a recognised feature of severe bilirubin neurotoxicity and may be the presenting sign; a jaundiced baby with apnoea needs an immediate exchange transfusion, not a sleep study.^[7]
• Low-bilirubin kernicterus in preterm infants: the most treacherous pitfall. Preterm infants develop kernicterus at TSB levels considered "safe" in term infants, because their blood-brain barrier is more permeable and albumin lower. The threshold graph must be read for the correct gestation, and unwell preterm infants treated at lower levels.^[7]
• Rebound after phototherapy: stopping phototherapy too early leads to a rebound, especially in haemolysis and prematurity; always re-check 12 to 24 hours after stopping.^[3]
• Mislabelling pathological jaundice "physiological": the cardinal error. Jaundice in the first 24 hours, a rapidly rising bilirubin, a conjugated fraction, or a sick infant is never physiological.^[1]
• Missed biliary atresia: reassuring "breast milk jaundice" in a 4-week-old with pale stools. Check the stool colour and the conjugated fraction in every prolonged jaundice.^[6]
• Over-reliance on visual estimation: Kramer's rule under-reads in dark skin and in bright phototherapy light; always measure serum bilirubin.^[1]
• Failing to read the nomogram by hours: a bilirubin of 13 mg per dL is normal at 96 hours but pathological at 12 hours.^[2]

Prognosis & Disposition

Physiological jaundice resolves completely and has an excellent prognosis. Treated haemolytic jaundice that is brought below the encephalopathy threshold has a good prognosis, provided kernicterus has not developed. Once chronic kernicterus is established the damage is permanent: choreoathetoid cerebral palsy, sensorineural hearing loss (the most common and often the earliest detected by newborn hearing screening), dental dysplasia, gaze palsy and variable cognitive impairment, with life-long disability. Biliary atresia prognosis is dominated by the age at Kasai: successful bile drainage is achieved in roughly 50 to 70% when the Kasai is performed before 60 days and falls steeply thereafter; many children still progress to cirrhosis and need liver transplantation, which is curative.^[6]

Disposition follows the bilirubin trajectory. Below the phototherapy threshold and clinically well: outpatient with a follow-up bilirubin at the appropriate interval and feeding support. At or above the phototherapy threshold: inpatient phototherapy; discharge when the level is clearly below threshold and falling, with a planned re-check — phototherapy should be used only for newborns who exceed the thresholds in the current AAP hour-specific phototherapy nomograms. At or above the exchange threshold, rising despite intensive phototherapy, or any sign of encephalopathy: neonatal unit, exchange transfusion, and senior paediatric and haematology input. Any raised direct bilirubin (over 1.0 mg per dL): timely paediatric gastroenterology, hepatology and surgical referral for exclusion of biliary atresia, as a time-critical pathway. The safety-net for every discharged jaundiced newborn is a written warning for parents, a named follow-up appointment, and open access if the baby becomes jaundiced, sleepy or feeds poorly.^[11][19]

Special Populations

Preterm and low-birth-weight infants carry the highest risk of both severe hyperbilirubinaemia and kernicterus. They have lower UGT activity, lower albumin and a more permeable blood-brain barrier, and they tolerate high bilirubin worse. Treatment thresholds are lower for lower gestational ages, read directly from the AAP 2022 or NICE threshold graphs; the concept of a single "safe level" does not apply. Low-bilirubin kernicterus — brain injury at TSB levels below the classical exchange threshold — is a recognised entity in this group and is the principal reason the preterm threshold was not raised in the 2022 AAP revision.^[7]

Late-preterm infants (34 to 36 weeks) are a particular trap: they look like term babies but behave like preterms, with slower maturation of conjugation, poorer feeding, greater weight loss and higher readmission rates. They are treated by the threshold graph for their gestation, not their appearance.^[1]

G6PD-deficient infants need trigger avoidance (no fava beans, no henna, careful drug selection), parental education, and a low threshold for treatment of any acute haemolytic episode; in endemic regions they may justify targeted newborn screening.^[8]

Infants of diabetic mothers have a higher rate of polycythaemia and jaundice; check haematocrit and treat polycythaemia if symptomatic.^[1]

Exclusively breastfed infants have a higher baseline jaundice; the task is to support feeding, recognise suboptimal intake jaundice, and not abandon breastfeeding.^[1]

Surgical and hepatobiliary infants (biliary atresia, choledochal cyst) are managed on a time-critical pathway: any conjugated jaundice in a baby under 8 weeks is a surgical referral, full stop.^[6]

Evidence, Guidelines & Regional Differences

The two dominant guidelines are the American Academy of Pediatrics 2022 revision (PMID 35927462) and NICE Clinical Guideline CG98 (UK, updated 2024). They agree on the principles — universal pre-discharge bilirubin assessment, hour-specific nomogram interpretation, phototherapy then exchange as a ladder, and aggressive treatment of haemolysis — but differ in detail.^[1]

The AAP 2022 revision (replacing the 2004 guideline) applies to infants of 35 or more weeks of gestation. It was informed by accumulating evidence of overtreatment and potential harms of phototherapy, and the new phototherapy thresholds are higher than in previous guidelines. Thresholds are presented as hour-specific nomograms based on gestational age at birth and the presence of neurotoxicity risk factors, and the guideline reconfirmed universal bilirubin screening in newborns of 35 or more weeks, with follow-up individualised by gestational age, neurotoxicity risk factors and the bilirubin-to-treatment-threshold difference.^[11][12][13]

The conversion between units matters at the bedside: a direct bilirubin cutoff of over 1.0 mg per dL is the same as over 17 micromol per L — the two units name one threshold. Whichever chart you use, read it with the risk profile of the baby: a haemolysing, preterm, ill infant is treated at a lower level than a well, term, low-risk infant at the same age.^[19]

Controversies persist: the ideal threshold for phototherapy in preterm infants (the 2022 AAP revision did not raise these as it did for term, fearing low-bilirubin kernicterus); the role of IVIG (Cochrane evidence is low-certainty); the duration of phototherapy after which rebound is unlikely; and the utility of unbound (free) bilirubin as a more direct measure of neurotoxicity than total bilirubin. The Bhutani nomogram (1999) remains the foundational interpretive tool, validated in healthy term and near-term infants; it is less directly applicable to sick or preterm babies, in whom the threshold graphs govern.^[2][4][5]

Exam Pearls

^[1]

Self-test: a baby at 18 hours has a TSB of 14 mg per dL, all unconjugated. What do you do?ShowHide

This is pathological jaundice — hyperbilirubinemia in the first 24 hours of life is pathologic and necessitates additional evaluation, and a level this high this early is on a haemolytic trajectory until proven otherwise (the Bhutani nomogram defines the high-risk zone as TSB at or above the 95th percentile for age in hours). Management: start intensive phototherapy immediately (phototherapy decreases the need for exchange transfusion); take blood for fractionated bilirubin, blood group (mother and baby), Coombs (DAT), FBC, reticulocytes, film, G6PD and sepsis screen; plot on the hour-specific nomogram; assess hydration and feeding; and have a low threshold for IVIG (if Coombs positive and rising — recognising that its evidence is low quality) and exchange transfusion (if the level reaches the exchange threshold or signs of encephalopathy appear). Rh sensitisation of the next pregnancy is prevented by anti-D, given at 28 or 30 weeks and within 72 hours of potential exposure to fetal red cells.^{[24][2][11][5][20]}

Exam application bank (NEET-PG / INICET)

One-line answer

Neonatal jaundice = yellow skin and sclera from elevated bilirubin in the first 28 days of life, visible when total serum bilirubin (TSB) exceeds 5 to 7 mg per dL (85 to 120 micromol per L). Jaundice within the FIRST 24 HOURS is always PATHOLOGICAL and demands urgent investigation for haemolysis and sepsis. Unconjugated (indirect) hyperbilirubinaemia (about 85%) is fat-soluble, crosses the immature blood-brain barrier, and causes kernicterus (acute bilirubin encephalopathy with lethargy, high-pitched cry, opisthotonus; chronic choreoathetoid cerebral palsy, sensorineural hearing loss). Conjugated (direct) hyperbilirubinaemia (about 15%) is water-soluble, does not cause kernicterus, but signals hepatobiliary disease — most importantly biliary atresia (pale stool, dark urine, conjugated jaundice) needing Kasai portoenterostomy before 60 days. Treatment is phototherapy (blue light converts ^[1]

Worked stems (answer without another resource)

Stem 1 — Classic presentation. Map symptoms to mechanism; name the first investigation and first treatment step with dose/route if drug therapy is standard. ^[1]

Stem 2 — Unstable / complicated. List red flags that force immediate resuscitation, theatre, ICU, antidote, or reperfusion — and what you do in the first 15 minutes. ^[1]

Stem 3 — Atypical group. Elderly, pregnancy, child, or immunocompromised: how presentation and thresholds change. ^[1]

Stem 4 — Differential trap. Name the three closest mimics and one discriminator for each. ^[1]

Stem 5 — Disposition. Who goes home with safety-netting, who is admitted, who needs HDU/ICU/theatre, and what follow-up is mandatory. ^[1]

Rapid viva checklist

1. Definition + classification
2. Pathophysiology chain
3. Bedside signs / criteria
4. Score with exact components (if any)
5. Emergency bundle
6. Definitive therapy with doses
7. Complications of disease and of treatment
8. Special populations
9. Guideline/trial name if classic
10. Three exam traps

Coverage self-check

If you cannot answer any stem above from this page alone, re-read the matching section — the page is intended to be self-sufficient for final-prof and NEET-PG/INICET questions on Neonatal Jaundice.

References25ShowHide

1. [1]Kemper AR, Newman TB, Slaughter JL, et al. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation Pediatrics, 2022.PMID 35927462
2. [2]Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns Pediatrics, 1999.PMID 9917432
3. [3]Maisels MJ, McDonagh AF. Phototherapy for neonatal jaundice N Engl J Med, 2008.PMID 18305267
4. [4]Watchko JF. Vigintiphobia revisited Pediatrics, 2005.PMID 15930239
5. [5]Zwiers C, Scheffer-Rath ME, Lopriore E, et al. Immunoglobulin for alloimmune hemolytic disease in neonates Cochrane Database Syst Rev, 2018.PMID 29551014
6. [6]Tyraskis A, Davenport M Steroids after the Kasai procedure for biliary atresia: the effect of age at Kasai portoenterostomy Pediatr Surg Int, 2016.PMID 26590818
7. [7]Watchko JF. The enigma of low bilirubin kernicterus in premature infants: why does it still occur, and is it preventable? Semin Perinatol, 2014.PMID 25267279
8. [8]Arain YH, Bhutani VK Prevention of Kernicterus in South Asia: role of neonatal G6PD deficiency and its identification Indian J Pediatr, 2014.PMID 24763814
9. [9]Hansen TWR, Maisels MJ, Ebbesen F, et al. Sixty years of phototherapy for neonatal jaundice - from serendipitous observation to standardized treatment and rescue for millions J Perinatol, 2020.PMID 31420582
10. [10]Anderson NB, Calkins KL. Neonatal Indirect Hyperbilirubinemia NeoReviews, 2020.PMID 33139512
11. [11]Par EJ, Hughes CA, DeRico P. Neonatal Hyperbilirubinemia: Evaluation and Treatment Am Fam Physician, 2023.PMID 37192079
12. [12]Sarathy L, Chou JH, Romano-Clarke G, et al. Bilirubin Measurement and Phototherapy Use After the AAP 2022 Newborn Hyperbilirubinemia Guideline Pediatrics, 2024.PMID 38482582
13. [13]Lueangapapong N, Srinithiwat B, Jangmeonwai P, et al. Clinical outcomes of the 2022 AAP hyperbilirubinemia guideline in term and late-preterm infants: a prospective study in Thailand Ital J Pediatr, 2026.PMID 42106782
14. [14]Nasseri F, Mamouri GA, Babaei H. Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn Saudi Med J, 2006.PMID 17143357
15. [15]Murki S, Dutta S, Narang A, et al. A randomized, triple-blind, placebo-controlled trial of prophylactic oral phenobarbital to reduce the need for phototherapy in G6PD-deficient neonates J Perinatol, 2005.PMID 15716985
16. [16]Murki S, Kumar P. Blood exchange transfusion for infants with severe neonatal hyperbilirubinemia Semin Perinatol, 2011.PMID 21641492
17. [17]Tan KL, Jacob E. The bronze baby syndrome Acta Paediatr Scand, 1982.PMID 7136654
18. [18]Petersen JP, Henriksen TB, Hollegaard MV, et al. Extreme neonatal hyperbilirubinemia and a specific genotype: a population-based case-control study Pediatrics, 2014.PMID 25092941
19. [19]Fawaz R, Baumann U, Ekong U, et al. Guideline for the Evaluation of Cholestatic Jaundice in Infants J Pediatr Gastroenterol Nutr, 2017.PMID 27429428
20. [20]Okwundu CI, Afolabi BB. Intramuscular versus intravenous anti-D for preventing Rhesus alloimmunization during pregnancy Cochrane Database Syst Rev, 2013.PMID 23440818
21. [21]Ngeow AJH, Moosa AS, Tan MG, et al. Development and Validation of a Smartphone Application for Neonatal Jaundice Screening JAMA Netw Open, 2024.PMID 39661385
22. [22]Newman TB, Liljestrand P, Escobar GJ. Infants with bilirubin levels of 30 mg/dL or more in a large managed care organization Pediatrics, 2003.PMID 12777545
23. [23]Schwartz HP, Haberman BE, Ruddy RM. Hyperbilirubinemia: current guidelines and emerging therapies Pediatr Emerg Care, 2011.PMID 21926893
24. [24]Bernardo EO, Matos RI, Dawood T, et al. Maternal cautopyreiophagia as a rare cause of neonatal hemolysis: a case report Pediatrics, 2015.PMID 25713278
25. [25]Ng MC, How CH. When babies turn yellow Singapore Med J, 2015.PMID 26668403